Current File : /var/www/html/digiprint/public/site/go8r5d/cache/f008de2c89d7c48fdf4264fe3bb0887d
a:5:{s:8:"template";s:9437:"<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<title>{{ keyword }}</title>
<link href="//fonts.googleapis.com/css?family=Open+Sans%3A300%2C400%2C600%2C700%2C800%7CRoboto%3A100%2C300%2C400%2C500%2C600%2C700%2C900%7CRaleway%3A600%7Citalic&subset=latin%2Clatin-ext" id="quality-fonts-css" media="all" rel="stylesheet" type="text/css"/>
<style rel="stylesheet" type="text/css"> html{font-family:sans-serif;-webkit-text-size-adjust:100%;-ms-text-size-adjust:100%}body{margin:0}footer,nav{display:block}a{background:0 0}a:active,a:hover{outline:0}@media print{*{color:#000!important;text-shadow:none!important;background:0 0!important;box-shadow:none!important}a,a:visited{text-decoration:underline}a[href]:after{content:" (" attr(href) ")"}a[href^="#"]:after{content:""}p{orphans:3;widows:3}.navbar{display:none}}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}html{font-size:62.5%;-webkit-tap-highlight-color:transparent}body{font-family:"Helvetica Neue",Helvetica,Arial,sans-serif;font-size:14px;line-height:1.42857143;color:#333;background-color:#fff}a{color:#428bca;text-decoration:none}a:focus,a:hover{color:#2a6496;text-decoration:underline}a:focus{outline:thin dotted;outline:5px auto -webkit-focus-ring-color;outline-offset:-2px}p{margin:0 0 10px}ul{margin-top:0;margin-bottom:10px}.container{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}@media (min-width:768px){.container{width:750px}}@media (min-width:992px){.container{width:970px}}@media (min-width:1200px){.container{width:1170px}}.container-fluid{padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}.row{margin-right:-15px;margin-left:-15px}.col-md-12{position:relative;min-height:1px;padding-right:15px;padding-left:15px}@media (min-width:992px){.col-md-12{float:left}.col-md-12{width:100%}}.collapse{display:none} .nav{padding-left:0;margin-bottom:0;list-style:none}.nav>li{position:relative;display:block}.nav>li>a{position:relative;display:block;padding:10px 15px}.nav>li>a:focus,.nav>li>a:hover{text-decoration:none;background-color:#eee}.navbar{position:relative;min-height:50px;margin-bottom:20px;border:1px solid transparent}@media (min-width:768px){.navbar{border-radius:4px}}@media (min-width:768px){.navbar-header{float:left}}.navbar-collapse{max-height:340px;padding-right:15px;padding-left:15px;overflow-x:visible;-webkit-overflow-scrolling:touch;border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}@media (min-width:768px){.navbar-collapse{width:auto;border-top:0;box-shadow:none}.navbar-collapse.collapse{display:block!important;height:auto!important;padding-bottom:0;overflow:visible!important}}.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:-15px;margin-left:-15px}@media (min-width:768px){.container-fluid>.navbar-collapse,.container-fluid>.navbar-header{margin-right:0;margin-left:0}}.navbar-brand{float:left;height:50px;padding:15px 15px;font-size:18px;line-height:20px}.navbar-brand:focus,.navbar-brand:hover{text-decoration:none}@media (min-width:768px){.navbar>.container-fluid .navbar-brand{margin-left:-15px}}.navbar-nav{margin:7.5px -15px}.navbar-nav>li>a{padding-top:10px;padding-bottom:10px;line-height:20px}@media (min-width:768px){.navbar-nav{float:left;margin:0}.navbar-nav>li{float:left}.navbar-nav>li>a{padding-top:15px;padding-bottom:15px}.navbar-nav.navbar-right:last-child{margin-right:-15px}}@media (min-width:768px){.navbar-right{float:right!important}}.clearfix:after,.clearfix:before,.container-fluid:after,.container-fluid:before,.container:after,.container:before,.nav:after,.nav:before,.navbar-collapse:after,.navbar-collapse:before,.navbar-header:after,.navbar-header:before,.navbar:after,.navbar:before,.row:after,.row:before{display:table;content:" "}.clearfix:after,.container-fluid:after,.container:after,.nav:after,.navbar-collapse:after,.navbar-header:after,.navbar:after,.row:after{clear:both}@-ms-viewport{width:device-width}html{font-size:14px;overflow-y:scroll;overflow-x:hidden;-ms-overflow-style:scrollbar}@media(min-width:60em){html{font-size:16px}}body{background:#fff;color:#6a6a6a;font-family:"Open Sans",Helvetica,Arial,sans-serif;font-size:1rem;line-height:1.5;font-weight:400;padding:0;background-attachment:fixed;text-rendering:optimizeLegibility;overflow-x:hidden;transition:.5s ease all}p{line-height:1.7;margin:0 0 25px}p:last-child{margin:0}a{transition:all .3s ease 0s}a:focus,a:hover{color:#121212;outline:0;text-decoration:none}.padding-0{padding-left:0;padding-right:0}ul{font-weight:400;margin:0 0 25px 0;padding-left:18px}ul{list-style:disc}ul>li{margin:0;padding:.5rem 0;border:none}ul li:last-child{padding-bottom:0}.site-footer{background-color:#1a1a1a;margin:0;padding:0;width:100%;font-size:.938rem}.site-info{border-top:1px solid rgba(255,255,255,.1);padding:30px 0;text-align:center}.site-info p{color:#adadad;margin:0;padding:0}.navbar-custom .navbar-brand{padding:25px 10px 16px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{color:#f8504b}a{color:#f8504b}.navbar-custom{background-color:transparent;border:0;border-radius:0;z-index:1000;font-size:1rem;transition:background,padding .4s ease-in-out 0s;margin:0;min-height:100px}.navbar a{transition:color 125ms ease-in-out 0s}.navbar-custom .navbar-brand{letter-spacing:1px;font-weight:600;font-size:2rem;line-height:1.5;color:#121213;margin-left:0!important;height:auto;padding:26px 30px 26px 15px}@media (min-width:768px){.navbar-custom .navbar-brand{padding:26px 10px 26px 0}}.navbar-custom .navbar-nav li{margin:0 10px;padding:0}.navbar-custom .navbar-nav li>a{position:relative;color:#121213;font-weight:600;font-size:1rem;line-height:1.4;padding:40px 15px 40px 15px;transition:all .35s ease}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0}@media (max-width:991px){.navbar-custom .navbar-nav{letter-spacing:0;margin-top:1px}.navbar-custom .navbar-nav li{margin:0 20px;padding:0}.navbar-custom .navbar-nav li>a{color:#bbb;padding:12px 0 12px 0}.navbar-custom .navbar-nav>li>a:focus,.navbar-custom .navbar-nav>li>a:hover{background:0 0;color:#fff}.navbar-custom li a{border-bottom:1px solid rgba(73,71,71,.3)!important}.navbar-header{float:none}.navbar-collapse{border-top:1px solid transparent;box-shadow:inset 0 1px 0 rgba(255,255,255,.1)}.navbar-collapse.collapse{display:none!important}.navbar-custom .navbar-nav{background-color:#1a1a1a;float:none!important;margin:0!important}.navbar-custom .navbar-nav>li{float:none}.navbar-header{padding:0 130px}.navbar-collapse{padding-right:0;padding-left:0}}@media (max-width:768px){.navbar-header{padding:0 15px}.navbar-collapse{padding-right:15px;padding-left:15px}}@media (max-width:500px){.navbar-custom .navbar-brand{float:none;display:block;text-align:center;padding:25px 15px 12px 15px}}@media (min-width:992px){.navbar-custom .container-fluid{width:970px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}}@media (min-width:1200px){.navbar-custom .container-fluid{width:1170px;padding-right:15px;padding-left:15px;margin-right:auto;margin-left:auto}} @font-face{font-family:'Open Sans';font-style:normal;font-weight:300;src:local('Open Sans Light'),local('OpenSans-Light'),url(http://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN_r8OXOhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(http://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFW50e.ttf) format('truetype')} @font-face{font-family:Roboto;font-style:normal;font-weight:700;src:local('Roboto Bold'),local('Roboto-Bold'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmWUlfChc9.ttf) format('truetype')}@font-face{font-family:Roboto;font-style:normal;font-weight:900;src:local('Roboto Black'),local('Roboto-Black'),url(http://fonts.gstatic.com/s/roboto/v20/KFOlCnqEu92Fr1MmYUtfChc9.ttf) format('truetype')} </style>
</head>
<body class="">
<nav class="navbar navbar-custom" role="navigation">
<div class="container-fluid padding-0">
<div class="navbar-header">
<a class="navbar-brand" href="#">
{{ keyword }}
</a>
</div>
<div class="collapse navbar-collapse" id="custom-collapse">
<ul class="nav navbar-nav navbar-right" id="menu-menu-principale"><li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-169" id="menu-item-169"><a href="#">About</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-121" id="menu-item-121"><a href="#">Location</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-120" id="menu-item-120"><a href="#">Menu</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-119" id="menu-item-119"><a href="#">FAQ</a></li>
<li class="menu-item menu-item-type-post_type menu-item-object-post menu-item-122" id="menu-item-122"><a href="#">Contacts</a></li>
</ul> </div>
</div>
</nav>
<div class="clearfix"></div>
{{ text }}
<br>
{{ links }}
<footer class="site-footer">
<div class="container">
<div class="row">
<div class="col-md-12">
<div class="site-info">
<p>{{ keyword }} 2021</p></div>
</div>
</div>
</div>
</footer>
</body>
</html>";s:4:"text";s:7310:"Zomedica Corp., formerly Zomedica Pharmaceuticals Corp., is a development stage veterinary diagnostic and pharmaceutical company. After treading water for much of 2020, ZOM stock is up 786% in 2021. Zomedica currently employs eight direct field sales personnel, supported by two regional managers, a Vice President of Sales, and a Chief Commercial Officer. TTM = trailing 12 months. Yes, you can argue that its still-inflated valuation ($947 million) is based on what Truforma’s sales could be several years down the road. Zomedica made $277,000,000 on extra shares they sold and purchased debt / preferred shares. Transforming veterinary diagnostics where it matters most TRUFORMA offers complete control over the testing process from start to finish, with highly sensitive and specific immunoassays that allow veterinarians to make clinical decisions faster — and begin treating patients sooner. In the press release, Zomedica said that it recorded its first official sale of TRUFORMA, taking the company from development stages to commercialization. Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA® and officially entered commercialization. But there’s a next-to-zero chance it can quickly grab the level of sales needed to justify its current market capitalization. Robert Cohen, Chief Executive Officer of Zomedica, commented: "As TRUFORMA's market presence grew, we intended to transition from a distributor-based sales model to a direct sales organization. 'This is a momentous day for Zomedica, our shareholders, the veterinarians we serve, and the companion animals in their care. hide. However, it’s just around the corner, and it will be a significant month for Zomedica… Truforma Q2 sales, ZM-022 release, dual Q3 sales, ZM-017 release, Q4 rockets. Zomedica currently employs eight direct field sales personnel, supported by two regional managers, a Vice President of Sales, and a Chief Commercial Officer. However, I think that the announcement is a good news. “This is a momentous day for Zomedica, our shareholders, … ®.. Additional information about TRUFORMA ® , Click TRUFORMA ® A tab at the top of the home page of the Zomedica website (www.zomedica.com). ZOM shares closed up 2% on Friday. The … But there’s a next-to-zero chance it can quickly grab the level of sales needed to justify its current market capitalization. "This is a momentous day for Zomedica… Schilk joined Zomedica in 2018, and has been essential in building the internal sales organization in anticipation of the commercial release of TRUFORMA™. ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) ("Zomedica" or the "Company"), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA (R) and officially entered commercialization. 100% Upvoted. Protected by approximately 70 issued and pending patents, the TRUFORMA diagnostic platform uses Bulk Acoustic Wave (“BAW”) technology, developed by Qorvo to provide a non-optical and fluorescence-free detection system for use at the point-of-care. … Play. Zomedica currently employs eight direct field sales personnel, supported by two regional managers, a Vice President of Sales, and a Chief Commercial Officer. ZOM shares closed up 2% on Friday. Zomedica Announces First Commercial Sale of Its Truforma® Platform ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or … Based on TRUFORMA sales expectations, current share count, and future growth, I believe that ZOM shares' value is in the range of $0.8 to $1.2 per share. The company’s announcement last Thursday that was not concerned by investors and the stock continues to fall. The expansion of a direct sales team and organization for ZOM and TRUFORMA ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA ® and officially entered commercialization. The veterinarian in charge of the facility is Dr. Jason Berg, who is excited to be the first official user of the Truforma … Zomedica Corp. (NYSE American: ZOM) (' Zomedica ' or the 'Company'), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA and officially entered commercialization. We look forward to working together with Zomedica to introduce TRUFORMA to our many valued customers and the pets in their care.” “This is a momentous day for Zomedica, our shareholders, … TRUFORMA ™ is Zomedica’s flagship product that is expected to launch in the near term alongside a digital customer data platform which will connect the line of products and the company’s diagnostic pipeline. I personally believe they have sold at least 25-50 units within that period. We are fortunate to have Zomedica financially strong to make this transition and look forward to building a quality sales force that is comparable to TRUFORMA’s superior quality. report. View Comments. March may seem like a long way off. Zomedica to build direct sales force for TRUFORMA platform Apr. Zomedica (NYSEAMERICAN:ZOM) is a pre-revenue company that is about to bring its first product to market.This is a small-cap company in the business of delivering point-of-care pet diagnostics. We are fortunate that we have the financial strength at Zomedica to make this transition, and look forward to building a quality sales force to match the excellent quality of TRUFORMA (R)." Robert Cohen, Chief Executive Officer of Zomedica, commented: “As TRUFORMA®’s market presence grew, we intended to transition from a distributor-based sales model to a direct sales … Zomedica Corp.(NYSE:ZOM): Zomedica (ZOM), which develops diagnostic and pharmaceutical products for companion animals, saw little share price fluctuation over the past few years until the penny stock soared after being promoted on Netflix earlier this year. Even if there are no reported sales. save. Zomedica Will Launch TRUFORMA Soon. Zomedica Climbs on TRUFORMA Sale. ANN ARBOR, Mich., March 16, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, yesterday recorded the first veterinarian sale of TRUFORMA ® and officially entered commercialization. Zomedica may have locked down its first Truforma sale last month. Novel assays to aid in correct diagnosis The first feline-optimized TSH assay, which will help veterinarians […] Zomedica announced on March 16 the first official sale of its Truforma platform to a veterinarian in the U.S. Zomedica’s first customer was an animal hospital in … As our sales effort begins, we intend to implement a controlled release phase wherein we slowly begin the sale of the TRUFORMA instrument and at … ";s:7:"keyword";s:23:"zomedica truforma sales";s:5:"links";s:820:"<a href="http://digiprint.coding.al/site/go8r5d/how-to-schedule-an-appointment-in-outlook-2016">How To Schedule An Appointment In Outlook 2016</a>,
<a href="http://digiprint.coding.al/site/go8r5d/whatsapp-square-clock-icon">Whatsapp Square Clock Icon</a>,
<a href="http://digiprint.coding.al/site/go8r5d/axe-africa-deodorant-spray">Axe Africa Deodorant Spray</a>,
<a href="http://digiprint.coding.al/site/go8r5d/uc-health-covid-vaccine-colorado">Uc Health Covid Vaccine Colorado</a>,
<a href="http://digiprint.coding.al/site/go8r5d/best-stock-trading-app-canada">Best Stock Trading App Canada</a>,
<a href="http://digiprint.coding.al/site/go8r5d/avant-dealers-in-ireland">Avant Dealers In Ireland</a>,
<a href="http://digiprint.coding.al/site/go8r5d/shogun-burger-mcdonald%27s-price">Shogun Burger Mcdonald's Price</a>,
";s:7:"expired";i:-1;}
Mini Shell